Pages that link to "Q33345998"
Jump to navigation
Jump to search
The following pages link to A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia (Q33345998):
Displaying 50 items.
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes (Q26752940) (← links)
- Guidelines for the management of myeloproliferative neoplasms (Q26778326) (← links)
- Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors (Q26863610) (← links)
- Advances in the management of myelofibrosis (Q27008072) (← links)
- The evolving treatment paradigm in myelofibrosis (Q27021968) (← links)
- Practical management of classical myeloproliferative disorder patients: a clinician's guide (Q28200207) (← links)
- Thalidomide for the treatment of idiopathic myelofibrosis (Q33359542) (← links)
- Modern management of myelofibrosis (Q33365122) (← links)
- Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis (Q33386057) (← links)
- Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia (Q33389328) (← links)
- New drugs for the treatment of myelofibrosis (Q33389330) (← links)
- A phase-2 trial of low-dose pomalidomide in myelofibrosis (Q33392689) (← links)
- Immunomodulatory agents in myelofibrosis (Q33401615) (← links)
- Emerging drugs for myelofibrosis (Q33404574) (← links)
- Ruxolitinib: a new treatment option for myelofibrosis (Q33405241) (← links)
- Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study (Q33406035) (← links)
- Thalidomide treatment in a myelofibrosis patient with leukemia transformation (Q33411894) (← links)
- Long-term results of prednisone treatment for the anemia of myelofibrosis. (Q33422565) (← links)
- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. (Q33423956) (← links)
- Alleviating anemia and thrombocytopenia in myelofibrosis patients (Q33430113) (← links)
- Safety considerations when treating myelofibrosis (Q33432285) (← links)
- Managing patients with myelofibrosis and low platelet counts (Q33432406) (← links)
- Outcome of transplantation for myelofibrosis (Q34015474) (← links)
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia (Q34146512) (← links)
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations (Q34150008) (← links)
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies (Q34158356) (← links)
- Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial (Q34162867) (← links)
- Pomalidomide therapy for multiple myeloma and myelofibrosis: an update (Q34165935) (← links)
- Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies (Q34253548) (← links)
- Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms (Q34302770) (← links)
- Modest activity of pomalidomide in patients with myelofibrosis and significant anemia (Q34512203) (← links)
- Choosing between stem cell therapy and drugs in myelofibrosis (Q34734491) (← links)
- Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα. (Q35203067) (← links)
- Profile of pomalidomide and its potential in the treatment of myelofibrosis (Q35427915) (← links)
- The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation (Q35849342) (← links)
- Thalidomide for the treatment of multiple myeloma (Q35870500) (← links)
- Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. (Q35937081) (← links)
- New approaches in the treatment of myelofibrosis (Q35964242) (← links)
- Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies (Q36001930) (← links)
- Thalidomide and immunomodulatory drugs in the treatment of cancer (Q36040871) (← links)
- Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis (Q36047069) (← links)
- Idiopathic myelofibrosis: pathogenesis to treatment (Q36396209) (← links)
- Ruxolitinib for myelofibrosis (Q36604028) (← links)
- Allogeneic stem cell transplantation as treatment for myelofibrosis (Q36609417) (← links)
- The evolving role of lenalidomide in the treatment of hematologic malignancies (Q36739807) (← links)
- New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape (Q36782943) (← links)
- Myelofibrosis: biology and treatment options (Q36922494) (← links)
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (Q37163590) (← links)
- Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis (Q37216367) (← links)
- Miscreant myeloproliferative disorder stem cells (Q37299267) (← links)